Amer Zeidan, MBBS
Associate Professor of Internal Medicine (Hematology)Cards
About
Research
Overview
The focus of my clinical/translational research is the development of novel therapies for MDS, AML, and other hematologic malignancies. Dr. Zeidan is the principal investigator on several clinical trials in MDS, AML and other hematologic malignancies. Dr. Zeidan especially focuses on the use of immunotherapies (drugs that stimulate the patient's own immune system) including the immune checkpoint inhibitors to fight blood cancers.
Clinical research; Novel therapies
Medical Subject Headings (MeSH)
Academic Achievements & Community Involvement
Clinical Care
Overview
Amer Zeidan, MBBS (a medical degree awarded in several countries outside the U.S.), MHS, is a hematologist who specializes in treating and researching myeloid malignancies.
Myeloid malignancies occur when healthy blood cells throughout the body and in bone marrow do not mature normally and instead replicate, proliferate, or transform in other ways. Dr. Zeidan’s research and clinical care focus on targeting therapies to a patient’s diagnosis and working with their own immune system to counter the malignancies.
At Yale Cancer Center, Dr. Zeidan is the medical director of Hematology Early Therapeutics Research, leader of the Disease Aligned Research Team (DART) for Leukemia and Myeloid Malignancies, and the assistant director of the Clinical Trials Office for hematology.
His research efforts focus on finding new, active, and safe therapies for blood cancers through clinical trials. He also explores why certain standard therapies have not been as effective in practice as they have been in clinical trials, and how the performance of these therapies can be improved in the clinic.
Dr. Zeidan has received many awards, including the Leukemia and Lymphoma Society Scholar in Clinical Research award and the National Cancer Institute Cancer Clinical Investigator Team Leadership award. He serves on the editorial boards of several key hematology and oncology publications, and is the author of more than 260 peer-reviewed studies and chapters of books.
Clinical Specialties
Fact Sheets
Myelodysplastic/Myeloproliferative Neoplasms
Learn More on Yale MedicineCytogenic Studies for Leukemia Diagnosis
Learn More on Yale MedicineChronic Myeloid Leukemia (CML)
Learn More on Yale MedicineMyelodysplastic Syndromes
Learn More on Yale Medicine
Board Certifications
Hematology (Internal Medicine)
- Certification Organization
- AB of Internal Medicine
- Latest Certification Date
- 2019
- Original Certification Date
- 2013
Yale Medicine News
News & Links
News
- September 30, 2024
YCC Publications 2024
- July 10, 2024Source: Targeted Oncology
COMMANDS Trial Shows Positive Result in MDS Despite Pandemic
- June 27, 2024Source: Oncology Nursing News
Luspatercept Improves Response Rates, Transfusion Independence for Lower-Risk MDS
- June 07, 2024
New Treatment Approved for Certain Patients Living With Myelodysplastic Syndromes